Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide mainly present in sensory nerve fibers, which is present in almost all organs, but it is also found in cultured rat type II alveolar epithelial cells (AEII). Our data have previously shown that CGRP may play an important role in inflammation as an immunomodulator. Proinflammatory factor IL-1β induces CGRP release from neuron-derived sources. However, whether IL-1β can induce CGRP secretion from a nonneural source, AEII cells, is not known. In the present study, we demonstrated that human AEII A549 cells expressed β-CGRP, and IL-1β (0.001−50 ng/ml) directly increased CGRP secretion from these cells in a time-and concentration-dependent manner. The mRNA level of β-CGRP was also elevated by IL-1β (1 ng/ml). In addition, we found that IL-1β-induced CGRP production was mediated through the PKC-p38 mitogen-activated protein (MAP) kinase-NF-κB signaling pathway. Furthermore, IL-1β-induced chemokines MCP-1 and IL-8 were partially inhibited by exogenous hCGRP (0.1−10 nM) and potentiated by hCGRP 8−37 (0.1−10 nM), a CGRP 1 -receptor antagonist. In addition, the CGRP-inhibited chemokine effect was partially reduced by Rp-cAMP, a cAMP-PK inhibitor. These results suggest that AEII-derived CGRP may act in an autocrine/paracrine mode and play an important inhibitory role in the local area in lung inflammatory diseases.
Cell culture
A549 cells, a human pulmonary epithelial carcinoma cell line with AEII differentiation, were obtained from the American Type Culture Collection (Rockville, MD) and grown in DMEM containing 10% FBS and penicillin/streptomycin (100 U/ml) in a humidified 37°C incubator. When confluent, cells were disaggregated in trypsin solution, washed in DMEM, centrifuged at 125 g for 5 min, then resuspended and subcultured according to standard protocols. Before being treated with chemicals, the cells were washed with DMEM twice and maintained in DMEM without FBS at 37°C for 4 h. To avoid peptide degradation, 1 µg/ml aprotinin was added to every experimental group when the cells were incubated with CGRP or hCGRP 8−37 .
Preparation of cell extracts and Western blot analysis
A549 cells were cultured in 10-cm petri dishes. After reaching confluence, cells were treated with IL-1β (1 ng/ml) or pretreated with inhibitors, followed by IL-1β, and incubated in a humidified incubator at 37°C. After incubation, the cells were rapidly washed with phosphate-buffered saline (PBS), and then lysed with ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 1 mg/ml pepstatin A, 20 mg/ml aprotinin, 1 mM NaF, and 1 mM Na 3 VO 4 ); lysates were subjected to SDS-PAGE with a 10% running gel. The proteins were transferred to a polyvinylidene fluoride membrane. The membrane was incubated successively with 0.1% bovine serum albumin in tris tween buffered saline (TTBS) at room temperature for 1 h, with rabbit Abs specific for phosphorylated or nonphosphorylated MAPKs at 4°C for 12 h and then with horseradish peroxidase-labeled second antibody for 1 h. After each incubation, the membrane was washed extensively with TTBS, and the immunoreactive band was detected with use of ECL-detecting reagents (Pierce, Biotechnology, Inc., IL).
Analysis of PKC-γ translocation
For the detection of protein kinase C (PKC) translocation, cytosolic, and membrane fractions were separated as described previously (23) . Briefly, after the treatment, the cells were scraped and collected, homogenized in ice-cold homogenization buffer [20 mM Tris, 2mM EDTA, 5 mM EGTA, 20% glycerol (v/v), 2 mM PMSF, 1% aprotinin (v/v), 5 mM DTT] for 20 min, then sonicated for 10 s and centrifuged at 800 g for 10 min. The supernatant (cytosolic and membrane fractions) was removed and centrifuged at 25,000 g for 15 min. The supernatant (cytosolic fraction) was obtained. The pellet (membrane fraction) was washed with the homogenization buffer and solubilized in homogenization buffer containing 0.1% NP-40. The protein levels of PKC-γ in cytosolic and membrane fractions were determined by Western blotting.
Immunofluorescence staining
A549 cells grown on coverslips were treated for 24 h with chemicals in growth medium. The cells were then rapidly washed with PBS and fixed at room temperature for 30 min with 4% paraformaldehyde. After being washed with PBS, cells were blocked for 30 min with 25 µg/ml avidin in TTBS, then incubated with rabbit anti-human CGRP Ab plus 3% goat serum for 12 h at 4°C. They were washed and treated with secondary biotin-labeled goat anti-rabbit Abs for 1 h, then washed and stained with 30 µg/ml rhodamine red-x-conjugated streptavidin at 37°C for 30 min. Cells were washed 3 times with PBS and viewed under a confocal laser-scanning microscope (Leica Co., Germany).
Formalin-fixed, paraffin-embedded sections of normal BALB/c mice lung were deparaffinized in xylene, then hydrated in graded ethanol concentrations. After being washed with PBS, sections were blocked for 15 min with 1% BSA in TTBS and then incubated with rabbit anti-human/mouse CGRP Ab for 12 h at 4°C. They were washed and incubated with goat anti-mouse SP-B Ab for 12 h at 4°C, then washed and treated with CY 5 -labeled donkey anti-rabbit Ab for 1 h at room temperature. Finally, they were washed and treated with FITC-labeled rabbit anti-goat Ab, then washed 3 times with PBS and viewed under a confocal laser-scanning microscope (Leica Co., Germany).
Radioimmunoassay of CGRP
The radioimmunoassay technique for the measurement of CGRP was similar to that used in our previous studies of CGRP release (15) . Briefly, samples were reconstituted in buffer (0.1 M phosphate buffer containing 0.1% BSA, 0.01% NaN 3 , 50 mM NaCl, and 0.1% Triton X-100, pH 7.4). Standards of synthetic CGRP (human amino acid sequence), ranging from ~2.5−1000 pg/assay tube, or the sample, dissolved in a volume of 0.2 ml buffer, were incubated for 24 h at 4°C with 0.1 ml of anti-CGRP Ab diluted in buffer. The mixture was then incubated for an additional 24 h at 4°C with 0.1 ml 125 I-labeled CGRP (10,000 cpm/tube) in buffer. Free and bound peptides were separated by the addition of 0.1 ml of goat anti-rabbit IgG (second Ab) and 0.1 ml of normal rabbit serum for 2 h at room temperature. An additional 0.5 ml of buffer was added, and the test tubes were centrifuged at 2,800 g at 4°C for 20 min. After the supernatant fraction was removed, gamma radioactivity of 125 I remaining in the tubes was measured.
Cytoplasmic RNA isolation and reverse-transcription polymerase chain reaction (RT-PCR)
The DMEM was removed, and the cells were washed twice with PBS. Then the RNAs were extracted with 1 ml Trizol and 0.2 ml chloroform and precipitated with 0.5 ml isopropanol. The suspension was kept at −70°C for 30 min and centrifuged at 12,000 g at 4°C for 15 min. The pellet was washed with 0.5 ml 70% ethanol and dried. RNA was stored at −70°C.
RT-PCR was performed as described previously (22) . Briefly, 2.0 µg total RNA and 1 µg oligo (dT) 15−17 was mixed for 10 min at 65°C and then quenched on ice. Then, 200 U each of moloney murine leukemia virus reverse transcriptase, deionized distilled diethylpyrocarbonate water, and reaction buffer solution were added, for a total reaction volume of 25 µl. This mixture was incubated at 37°C for 1 h. The reaction was terminated by heating at 95°C for 5 min and quenching on ice.
The oligonucleotide primers for CGRP were synthesized on a DNA synthesizer (Model 49a, Applied Biosystems, Inc., Foster City, CA). The oligonucleotides were constructed from the cDNA sequences of human α-CGRP and β-CGRP cDNA (24) . The sequences of the α-CGRP, β-CGRP and β-actin primers were as described previously (16) . The PCR amplification procedure consisted of denaturing at 94°C for 1 min, primer annealing at 58°C CGRP and β-actin for 1 min, and extension at 72°C for 1.5 min. PCR was run for 35 cycles. The PCR products were purified after PAGE with use of the Winzard plus Minipress DNA purification system (Promega, WI). Sequencing analysis was performed at Shanghai Jikang Biotechnology Corp. (Shanghai, China).
Hybridization and RNase protection assay (RPA)

Plasmid preparation
The plasmids pCGRPβ and pActin were constructed to allow the simultaneous quantification of human β-CGRP and β-actin gene-encoding transcripts, respectively. The PCR products β-CGRP and β-actin were ligated in pGEM-T Easy Vectors with T4 DNA ligase (all protocols were those of the pGEM-T and pGEM-T Easy Vectors Systems (Promega Co., Madison, WI).
Probe synthesis
Labeled RNA probes were synthesized with use of the T7/SP6 RiboQuant in Vitro Transcription Kit (PharMingen, La Jolla, CA) according to the manufacturer's instructions. From SalI-linearized pCGRPβ and ApaI-linearized pActin, we synthesized β-CGRP and β-actin probes, respectively, labeled with [α-32 ] UTP, at specific activity of 3−5 ×10 5 cpm/pg.
Hybridization
Standard RNAs (5−10 µg) were used for the assay. Probe-containing hybridization buffer (50 µl) was added. β-CGRP and β-actin probes (1 µg each) were used for hybridization. Hybridization and RNase protection assay involved use of the RiboQuant RNase Protection Assay Kit (PharMingen, San Diego, CA). For each RNA species, the signal was expressed as β-CGRP mRNA/β-actin mRNA. The length of the cDNAs was 295 and 156 bps for β-CGRP and β-actin, respectively.
Preparation of nuclear extracts and the electrophoretic mobility shift assay (EMSA)
Briefly, nuclear proteins were extracted with NE-PER TM Nuclear and Cytoplasmic Extraction Reagents (Pierce). EMSA involved use of the Gel Shift Assay Systems (Promega, Madison, WI). Briefly, the probes were end-labeled with [γ-32 P] ATP using T4 polynucleotide kinase. The nuclear extract (6-10 mg) was incubated at 30°C for 20 min with 1 ng 32 P-labeled probe (40,000-60,000 cpm) in 10 µl binding buffer. DNA/nuclear protein complexes were separated from the DNA probe by electrophoresis on a native 6% polyacrylamide gel; then the gel was vacuum-dried and subjected to autoradiography with an intensifying screen at −70°C. Probe sequence: NF-κB-5′-AGT TGA GGG GAC TTT CCC AGG C-3′, 3′-TCA ACT CCC CTG AAA GGG TCC G-5′; CREB-5′-AGA GAT TGC CTG ACG TCA GAG AGC TAG-3′, 3′-TCT CTA ACG GAC TGC AGT CTC TCG ATC-5′.
PKC activity assay
PKC activity in A549 cells was measured by use of a PKC assay kit (Upstate, Jingmei Biotech Co. Ltd. Lake Placid, NY). Briefly, 10 µl cell lysate was incubated with 10 µl assay dilution buffer II, 10 µl substrate cocktail, 10 µl PKA/CaMK inhibitor cocktail, 10 µl PKC lipid activator, and 10 µl magnesium/ATP cocktail containing 1 µl [γ-
32 P] ATP (~3000 Ci/mmol) for 10 min at 30°C, then 25 µl of aliquot was transferred to the center of P81 paper. The assay square was washed 3 times with 0.75% phosphoric acid and once with acetone, then transferred to a scintillation vial to which scintillation cocktail was added, then read in a scintillation counter.
CGRP receptor binding assay
Radioligand binding assays were performed as described previously (25) . Briefly, confluent cultures of A549 cells were exposed to from 1 × 10 −16 M to 1 × 10 −8 M 125 I CGRP with a specific activity of ≥2000 Ci/mmol in a final volume of 200 µl for 3 h on ice. A duplicate set of experiments in which 1 µM unlabeled CGRP was added to the binding buffer (50 mM Tris-Hcl, 5 mM MgCl 2 , 100 mM NaCl, 0.2% BSA, 0.1% bacitracin pH=7.4) was conducted to determine nonspecific binding. Duplicate unlabeled wells were used to count cell numbers. After being incubated with label, the supernatants were removed from the cultures. The monolayers of cells were washed twice with 300 µl PBS and then lysed with 200 µl 0.6% SDS in 10 M Tris-EDTA buffer for 10 min. The lysates and supernatants were measured for gamma radioactivity of 125 I to determine levels of bound and unbound ligand. In competition-binding studies, the cells were incubated with increasing concentrations (0.1 pM to 1 µM) of unlabeled hCGRP and 800 PM 125 I-CGRP, and the lysates and supernatants were measured for gamma radioactivity of 125 I to determine levels of bound and unbound ligand.
ELISA for IL-8 and MCP-1
The level of IL-8 and MCP-1 present in supernatants from IL-1β-stimulated A549 cells in the presence or the absence of hCGRP 8−37 /hCGRP was determined by ELISA (R&D Systems Inc., Minneapolis, MN)
Statistical analysis
The results were expressed as mean ± SEM. The data were analyzed with one-way ANOVA and the Student-Newman-Keuls test for multiple comparisons between groups. The paired t test was used for paired experiments.
RESULTS
CGRP expression in AEII cells
To investigate the universality of CGRP expression in cultured rat AEII cells (14), we used the doublestain immunofluorescence method for normal mice paraffin-embedded lung tissues (Fig.  1A) . The marker surfactant protein B (SP-B; green) indicates the AEII cells extruding from the alveolar lumen; CGRP (red) was expressed in its cytosol but the second antibody did not show off (Fig. 1B) . The percentage of CGRP-positive cells in SP-B-positive cells was ~97.5%. Figure  1C shows CGRP expression in the NEBs, used as a positive control. In addition, CGRP expression was seen in human A549 AEII cells (Fig. 1D) .
IL-1β induced the increased CGRP secretion in A549 cells
Exposure of A549 cells to IL-1β (1 ng/ml) resulted in a time-dependent secretion of CGRP ( Fig.  2A) . CGRP-like immunoreactivity (CGRP-LI) levels in the medium were significantly increased after 8 h incubation and further elevated after 36 h incubation. Treatment with IL-1β (0.001−50 ng/ml for 24 h) caused a concentration-dependent increase in CGRP secretion (Fig. 2B) . IL-1β-specific Ab (0.1 and 1 µg/ml) significantly attenuated the IL-1β-induced CGRP secretion, which indicates that IL-1β-stimulated CGRP secretion depends on IL-1β immune activity. Pretreating cells with cyclohexamide (CHA; 10 µM) or actinomycin D (Act D; 1 µM) for 30 min markedly decreased the IL-1β-induced secretion of CGRP, by 70.3% and 100%, respectively (Fig. 2C) , which suggests that the enhanced secretion of CGRP by IL-1β depends on de novo transcription and translation elevation. RT-PCR data showed that A549 cells expressed only β-CGRP (156 bp) not α-type CGRP (223 bp) (Fig. 2D) . RNase protection assay was performed to test the change in mRNA level, and the relative ratio showed that the level of β-CGRP mRNA was significantly increased at 0.5 h to 4 h after IL-1β administration in vitro (Fig. 2E) .
PKC mediated IL-1β-induced CGRP secretion
Although A549 cells can express PKC-α, -γ, -ι, -ε, -λ, -ξ and -µ, only PKC-γ is activated after IL-1β stimulation (23) . Exposure of the cells to IL-1β (1 ng/ml) for 10, 30, and 60 min caused translocation of PKC-γ isoforms from the cytosol to the membrane fraction (Fig. 3A) . In addition, the PKC activator phorbol myristate acetate (PMA; 5−50 nM for 24 h) directly triggered CGRP secretion in A549 cells (Fig. 3B) . To determine further whether PKC activation was involved in IL-1β-induced CGRP secretion, cells were pretreated with the PKC inhibitors Ro 31-8220 (Ro; 500 and 1000 nM) or calphostin C (Cal; 100 and 500 nM) for 30 min, which significantly attenuated the IL-1β-induced CGRP secretion (Fig. 3C) . After the addition of 500 nM PMA to the cells for 20 h to exhaust PKC, IL-1β-evoked PKC activity and CGRP secretion were completely inhibited ( Fig. 3D and 3E ), which indicates that PKC-γ may play an important role in IL-1β-induced CGRP secretion.
Involvement of p38 MAPK in IL-1β-evoked CGRP secretion
We investigated whether the phosphorylation of p38 and p44/42 MAPKs, which are downstream of PKC, was involved in IL-1β response. After IL-1β stimulation, the phosphorylation of p38 MAPK was significantly increased at 10 min and maximized at 20−30 min (Fig. 4A) , whereas the phosphorylated p44/42 MAPK level was unchanged (data not shown). SB203580 (SB; 0.6−6 µM), the inhibitor of p38 MAPK, completely blocked IL-1β-induced CGRP secretion, while the inhibitor of p44/42 MAPK, PD98059 (2−20 µM), had no such effect (Fig. 4B) . To determine further whether p38 MAPK was the downstream signal molecule of PKC, cells were pretreated with SB (6 µM) or Ro (1 µM) for 30 min before IL-1β (1 ng/ml) stimulation for 20 min; the phosphorylation of p38 MAPK was significantly attenuated (Fig. 4C) . After PKC was exhausted by 500 nM PMA for 20 h, IL-1β-induced p38 MAPK activity was inhibited as well (Fig. 4D) . These data suggest that p38 MAPK, downstream of PKC, is involved in IL-1β-induced CGRP secretion from A549 cells.
NF-κB participated in IL-1β-evoked CGRP secretion
In that NF-κB is an important transcript factor induced by IL-1β, gel-shift analysis with nuclear extracts from IL-1β-stimulated A549 cells were used to confirm the transactivation of NF-κB. As shown in Fig. 5A , IL-1β-induced NF-κB was activated as early as 20 min, and the level peaked at 1 h. To study further whether NF-κB was involved in the signal transduction pathway leading to IL-1β-stimulated CGRP secretion, cells pretreated with the NF-κB inhibitors pyrrolidine dithiocarbamate (PDTC, 10−30 µM) and MG 132 (10 and 30 µM) for 30 min before the addition of 1 ng/ml IL-1β showed significantly attenuated IL-1β-induced CGRP secretion (Fig. 5B) . To analyze further whether the PKC-p38-MAPK pathway was upstream of NF-κB, cells pretreated with the inhibitors Ro (1 µM), SB (6 µM), or PDTC (30 µM) before 1 ng/ml IL-1β stimulation for 1 h showed attenuated activation of NF-κB (Fig. 5C ), which indicates that the transcript factor NF-κB, as a target of PKC-p38-MAPK, participated in IL-1β-induced CGRP secretion from A549 cells. To define the binding site of the transcript factor in the promoter of β-CGRP, the TRANSFAC system was used to identify one NF-κBp65 binding motif 1768 bp upstream of the transcription start site (26) . The similarity of core sequence was 0.904 and that of the flanking one was 1.
Gene expression of CGRP
As indicated above, the level of β-CGRP mRNA was significantly increased at 0.5 to 4 h after IL-1β administration. Pretreating A549 cells for 30 min with IL-1β-specific antibody (Ab; 100 ng/ml), Act D (1 µM), CHA (10 µM), Cal (500 nM), Ro (1 µM), SB (6 µM), PDTC (30 µM), or MG 132 (10 µM) before 1 ng/ml IL-1β stimulation for 30 min significantly attenuated the mRNA level of IL-1β-induced β-CGRP (Fig. 6) .
Primary functional study of IL-1β-induced CGRP
The function of the synthesis and secretion of the neuroendocrine immune modulator CGRP in response to proinflammatory factor IL-1β stimulation aroused our interest. How does CGRP act in the inflammation process? At first, we considered an autocrine or paracrine factor, the basic element of which is the expression of a receptor. RT-PCR data showed that A549 cells expressed the CGRP-1 receptor (CRLR), a functional receptor of CGRP (Fig. 7A) . Equilibrium binding experiments with 125 I-CGRP were then performed to determine whether A549 cells specifically bind this peptide. The data showed that A549 cells bound CGRP in a specific and saturable manner (Fig. 7B) . Scatchard plot analysis revealed ~750 binding sites per cell with a K d of 2.0 × 0.1 nM (Fig. 7C ). This constant is consistent with K d values for CGRP receptors found on other cell types (27, 28) . The competition binding showed the specific bind with CGRP (Fig. 7D) . After the stimulation with IL-1β (1 ng/ml) for 24 h, the binding affinity was almost constant, but the binding sites increased to ~850 sites per cell (Fig. 7B, C) .
Results from a number of studies have shown that pulmonary epithelial cells, especially type II cells, help recruit inflammatory cells to the lungs by generating the chemokines IL-8 and MCP-1 in response to TNF-α and IL-1β (29, 30) . To investigate the effect of IL-1β-induced CGRP on level of IL-1β-induced chemokines, we used hCGRP 8-37, a CGRP-1 receptor antagonist, simultaneously with IL-1β, after incubation for 24 h. The supernatants were collected, and the level of IL-8 or MCP-1 was measured by ELISA (Fig. 8A) . hCGRP 8−37 at a very low concentration (0.1 nM) significantly enhanced the IL-1β-induced IL-8 and MCP-1 secretion. These data imply that endogenous CGRP might inhibit chemokine expression induced by a proinflammatory factor to reduce the recruitment of inflammatory cells and lessen the inflammation. To confirm the inhibitory effect of CGRP, cells were treated with IL-1β in combination with exogenous human CGRP (0.1−10 nM) for 24 h; ELISA results showed that exogenous CGRP reduced IL-1β-induced IL-8 and MCP-1 levels in a concentration-dependent manner (Fig. 8B) . Thus, as a neuroendocrine immune modulator, CGRP might play an inhibitory role in the inflammation progress in the lung.
It is well known that CGRP acts on its receptor, which is coupled to adenylyl cyclase, and leads to elevated levels of intracellular cAMP and its protein kinase (PK). To investigate further whether cAMP-PK mediated the CGRP effect, cells pretreated with Rp-cAMPs (11 µM), a cAMP-PK inhibitor, significantly attenuated the inhibitory effect of CGRP (Fig. 8C) . These data suggest that CGRP decreases IL-1β-induced chemokine products via, at least in part, the cAMP-PKC-dependent pathway in AEII cells.
DISCUSSION
We demonstrated for the first time that both human and mouse AEII cells express CGRP and proinflammatory cytokine IL-1β in vitro increases β-CGRP synthesis and secretion in a timeand concentration-dependent manner via the PKC-p38-MAPK-NF-κB pathway. By investigating the CGRP-1 receptor antagonist hCGRP and exogenous agonist hCGRP, we also showed that AEII cell-derived β-CGRP could suppress the inflammatory chemokine IL-8 and MCP-1 secretion induced by IL-1β.
CGRP is a highly conservative peptide, and in humans, two isoforms, α-and β-CGRP, differ only in 3 amino positions, and their functions are similar (1, 2) . In the lung, CGRP-like immunoreactivity is localized in the nerve fibers of the airway mucosa and around vascular smooth muscle (31, 32) and is also found in pulmonary neuroepithelial cells/NEBs, including Clara cells, mostly at the branching points of intrapulmonary airways (11, 12, 33) . Because of this unique distribution, CGRP reacts in response to hypoxia, low pH, allergic inflammation, nicotine, and physical stimuli. CGRP is predicted to be important in controlling lung circulation (2) and airway hyper-responsiveness (34) .
CGRP was also present in the cytosol in resting AEII cells (Fig. 1) and could be secreted spontaneously in A549 cells (Fig. 2) . This observation indicates that CGRP derived from AEII cells may play a role in the normal lung. We recently observed that intranasal administration of lipopolysaccharide (50 µg/50 µl) for 12 h induced the inflammation in BALB/c mice lungs and significantly increased CGRP and IL-1β levels in bronchoalveolar lavage fluid and lung tissue. CGRP content was especially elevated in AEII cells (data not shown), which indicates that CGRP localized in such cells may play a role in lung inflammatory diseases. Hastings and Hua (14) demonstrated that only β-CGRP is expressed in rat AEII cells, and CGRP secretion is stimulated by the PKC activator PMA. In light of their report, our results show that only β-CGRP is expressed in human A549 AEII cells, and IL-1β induction of CGRP secretion is PKC dependent. In addition, CGRP basal secretion in A549 cells was PKC-dependent since it was attenuated by PKC depletion (Fig. 3D) .
In resting cells, PKCs are located predominantly in the cytosol. After activation, they translocate to the membrane fraction and activate the downstream kinases through phosphorylation (35, 36) . The p44/42 and p38 MAPKs, which are conserved eukaryotic signaling pathways mediating the effects of extracellular stimuli, are candidate targets of PKC. They are distinguished by activating signals, substrate specificity, and cellular responses (37) . In the present study, after PKC was exhausted or blocked, IL-1β-induced p38 MAPK was significantly inhibited (Fig. 4C  and D) , which indicates that PKC is a potent upstream molecule of p38 MAPK involved in IL-1β-induced CGRP secretion. The activated p38 MAPK can directly activate IκB kinase β (IKKβ), which then phosphorylates the inhibitor of NF-κB, IκB. After the degradation of IκB, NF-κB is set free, and it translocates to nuclear binding the relative motifs to regulate the transcription of target genes (38) . p38 MAPK is required for NF-κB-dependent gene expression (39) . However, p38 MAPK activity was not completely inhibited by PKC exhaustion in our study, which suggests the presence of other PKC-independent signaling mechanisms mediating its activation.
As a capsaicin-sensitive neuropeptide, CGRP is released from sensory neurons in response to ischemia, cigarette smoking, bradykinin, prostaglandins, etc. Our previous work showed that IL-1β induces CGRP production via a PKC-and NF-κB-dependent pathway in dorsal root ganglion neurons of neonatal rats (20) . Besides its presence in the neural system, CGRP localizes in NEBs, which are innervated by sensory fibers (40) . CGRP-like immunoreactivity has recently been shown to be localized in rat thymocytes and mesenteric lymph node lymphocytes (15) and in human T lymphocytes (16) . Immuno-relative T cell mitogens Con A, PHA, or IL-2, can induce CGRP secretion and gene expression in human and rat lymphocytes, but neuron-sensitive substances such as capsaicin have no such effect in T cells (41) , which indicates a specific induced secretion of CGRP.
AEII cells, as "defenders of the alveolus," play important roles in normal pulmonary function and in the response of the lung to toxic compounds that may cause lung damage. AEII cells have many functions, such as the synthesis and secretion of surface-active material and other substances, modulation of the alveolar hypophase, adaptation in response to lung injury and direct or indirect interaction with inflammatory cells, including alveolar macrophages and leukocytes (42) . In response to various stimuli, AEII cells will secrete chemokines and cytokines, such as MCP-1, RANTES, IL-8, IL-6, and GM-CSF, and increase the expression of adhesion molecules ICAM-1 and VCAM-1. AEII cells express neuropeptides other than CGRP, such as neuropeptide FF (43) and adrenomedullin (44) . Thus, AEII cells may act as important immune tissue, taking part in immunomodulation in lung inflammatory disease (42) . It is interesting that neuropeptides are endogenous in this nonspecific immune tissue, both for intra-immune system regulation and probably also bidirectional communication between the immune and neuronal systems.
Many inflammatory diseases are accompanied by increased CGRP secretion and synthesis. The CGRP effect on immunomodulation has been discussed for a long time; some investigators consider the effect an inflammatory mediator. Rat α-CGRP has a chemotactic active fragment and can induce eosinophil migration in rat airways (45, 46) . CGRP has also been demonstrated to magnify IL-1β-induced edema in vivo (47) . In vitro, CGRP is reported to stimulate β integrin-mediated T cell adhesion to fibronectin (48) and induce proinflammatory factor IL-8 secretion (25, 49) . However, Clementi and colleagues (50) found the anti-inflammatory effects of CGRP in mouse ear inflammation. Reinshagen and associates (51, 52) reported on the protective function of CGRP in rabbit colitis, and we demonstrated that CGRP can attenuate multiple low-dose streptozotocin-induced insulitis and reduce the occurrence of diabetes in mice (53) . As well, lymphocyte-derived CGRP can inhibit Con A-induced proliferation and IL-2 production in rat thymocytes in an autocrine/paracrine mode (22) . In the present study, a very low concentration of hCGRP 8−37 (0.1 nM), ~10 times more than that of endogenous CGRP, significantly magnified the IL-1β-induced IL-8 and MCP-1 secretion (Fig. 7A) . And exogenous CGRP reduced IL-1β-induced chemokine levels in a concentration-dependent manner (Fig. 7B) , which indicates that endogenous CGRP may play an inhibitory role in the inflammatory process. In lung or airway inflammatory diseases, CGRP released from terminals of primary sensory afferents and neuroendocrine cells besides AEII cells leads to a high local concentration of CGRP. CGRP not only inhibits the immunoreactivity of lung epithelium to immune cells but also enhances the phagocytosis of the peripheral macrophages to attenuate the inflammation (54). Tran and associates (25) demonstrated that CGRP by itself induces IL-8 synthesis in resting human corneal epithelial cells; we observed this phenomenon in A549 cells as well (Fig. 7B) .
The contrary conclusions might derive from different experimental conditions: in resting or normal cells (25, 45, 48, 49) , CGRP might trigger inflammation but would attenuate the inflammatory reaction in reacting to other, more violent stimuli (50) (51) (52) (53) . Further studies need to be directed at the anti-inflammatory mechanism of CGRP. Millet and colleagues (55) showed that CGRP inhibits NF-κB activity, which participates in the IL-1β-induced chemokine expression.
Adrenomedullin is a 52-amino acid peptide with structural homology to CGRP. However, our data showed that it did not significantly inhibit IL-1β-induced chemokine secretion (data not shown), which indicates that the two peptides have different functions. In addition, hCGRP 8−37 failed to show a dose-dependent elevation in IL-1β-induced IL-8 and MCP-1 secretion, possibly because the peptide antagonist derived from part of the overall peptide may act as an agonist, especially at high concentrations. For this reason, we recently used the RNAi technique to "knock out" the β-CGRP gene in A549 cells. The initial result from a few clones showed that the basal and IL-1β-induced IL-8 and MCP-1 secretion in these clones was significantly magnified (data not shown).
In summary, IL-1β induced CGRP secretion via the PKC-p38-MAPK-NF-κB pathway in human A549 AEII cells. And by using the CGRP-1 receptor antagonist hCGRP 8−37 and exogenous agonist hCGRP, the cAMP-PK inhibitor, we also showed that AEII cell-derived β-CGRP could suppress inflammatory chemokine IL-8 and MCP-1 secretion induced by IL-1β via a cAMP-PK-dependent mechanism. This study provides new insight into the immunomodulating effects of endogenous CGRP from AEII cells under pathologic lung conditions. , and the experiment was repeated 3 times. *P < 0.05 vs. nontreated cells. #P < 0.05 compared with IL-1β alone. D) Ethidium bromide-stained gel containing α-, β-CGRP, and β-actin RT-PCR products amplified from RNA harvested from A549 cells and PHA (1 µg/ml, for 24 h)-stimulated human PBMC. E) Autoradiography of bands for β-actin and β-CGRP mRNA analyzed by RNase protection assay. Cells were incubated with 1 ng/ml IL-1β for the indicated time, then the total RNA was extracted and subjected to RPA. Lanes represent two protected fragments: the 295-bp β-actin and the 165-bp β-CGRP. The relative levels for β-CGRP were expressed as the band intensity ratio of mRNA (intensity of β-CGRP mRNA to intensity of β-actin mRNA). Data are mean ± SEM (n=3), and the experiment was repeated 3 times. *P < 0.05 compared with control. 3 . Involvement of PKC in IL-1β-induced CGRP secretion. A) Cells were pretreated with PBS or 1 ng/ml IL-1β for 10, 30, and 60 min; then the subcellular (cytosol and membrane) fractions were isolated and immunodetected with antibody specific for PKC-γ as described in "Materials and Methods". B) CGRP-LI levels in the medium of A549 cells incubated with various concentrations of phorbol myristate acetate (PMA; 5, 10, and 50 nM) for 24 h. C) Cells were preincubated with Ro 31-8220 (Ro; 10−1000 nM) or calphostin C (Cal; 50−500 nM) for 30 min before being incubated with 1 ng/ml IL-1β for 24 h. The medium was then removed and analyzed for CGRP-LI levels. D) Cells were pretreated with 500 nM PMA or PBS for 20 h, after being incubated with or without IL-1β for 30 min; then the cell lysates were collected and subjected to PKC assay. Relative PKC activity was shown by ratio to untreated control. E) Cells were pretreated with 500 nM PMA or PBS for 20 h, then washed with DMEM twice and cultured with or without 1 ng/ml IL-1β for 24 h. The medium was removed and analyzed for CGRP-LI levels. Data are mean ± SEM (n=4−6), and the experiment was repeated twice. *P < 0.05 vs. untreated cells, #P < 0.05 compared with IL-1β alone. IL-1β-stimulated CGRP secretion. A) Cells were treated with 1 ng/ml IL-1β for the indicated time, and whole-cell lysates were subjected to Western blotting with antibodies specific for the total or phosphorylated form (p-p38) of p38 MAPK. B) Cells were preincubated with SB 203580 (SB; 0.6 and 6 µM) or PD 98059 (PD; 2 and 20 µM) for 30 min before being incubated with 1 ng/ml IL-1β for 24 h. The medium was then removed and analyzed for CGRP-LI levels. Data are mean ± SEM (n=4-5), and the experiment was repeated twice. *P < 0.05 vs. untreated cells, #P<0.05 compared with IL-1β alone. C) Cells were pretreated with SB203580 (SB; 6 µM), Ro 31-8220 (Ro; 1 µM) or MG 132 (MG; 10 µM) for 30 min before being incubated with 1 ng/ml IL-1β for 20 min. The whole-cell lysates were subjected to Western blotting with antibodies specific for the total or phosphorylated form (p-p38) of p38 MAPK. D) A549 cells were pretreated with 500 nM phorbol myristate acetate (PMA) or PBS for 20 h before being stimulated with 1 ng/ml IL-1β or not for 20 min. The whole-cell lysates were subjected to Western blotting with antibodies specific for the total or phosphorylated form (p-p38) of p38 MAPK. expressed as the band intensity ratio of mRNA (intensity of β-CGRP mRNA to intensity of β-actin mRNA). Cells were preincubated with IL-1β specific antibody (Ab; 100 ng/ml), actinomycin D (Act D; 1 µM), cyclohexamide (CHA; 10 µM), calphostin C (Cal; 500 nM), Ro 31-8220 (Ro; 1 µM), SB203580 (SB; 6 µM), PDTC (30 µM) or MG 132 (MG; 10 µM) for 30 min before being incubated with 1 ng/ml IL-1β for 30 min, then the total RNA was extracted and subjected to RPA, and the relative levels were shown. Data are mean ± SEM (n=3−4), and the experiment was repeated 3 times, *P < 0.05 compared with control, #P < 0.05 compared with IL-1β alone. 
